In The News View All

  • Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the OD...
    AbstractBackgroundThe ODYSSEY OUTCOMES trial compared alirocumab with placebo, added to high-intensity or maximum tolerated statin treatment, after acute coronary syndrome (ACS) in 18,924 patients. Alirocumab reduced the first occurrence of the primary composite endpoint and was associated with fewer all-cause ...
    Published on 2018-11-14

Authors